Corcept Therapeutics (CORT) Q2 2026 earnings review
Lifyorli Launch Ignites Growth, Guidance Skyrockets
Corcept delivered a blowout quarter, decisively reversing the massive earnings loss seen in Q1. Total revenue surged 32% YoY to $256.1 million, crushing expectations. The standout driver was the inaugural quarter of Lifyorli (oncology), which contributed a staggering $47.6 million out of the gate. Meanwhile, the core Cushing's business (Korlym) fully recovered from Q1's pharmacy bottleneck, printing $208.6 million. Net income reversed from a $31.2 million loss in Q1 to a $43.0 million profit. Riding this momentum, management drastically raised FY26 revenue guidance to $1.1-$1.2 billion, signaling extreme confidence in Lifyorli's sustained adoption.
🐂 Bull Case
Lifyorli's $47.6 million debut proves the company's long-touted oncology thesis. With over 1,300 patients already on treatment, Corcept has successfully diversified away from its sole reliance on endocrinology.
The Q1 narrative that 'demand is high, but authorizations are lagging' was vindicated. Korlym revenue rebounded sharply to $208.6 million, proving that the underlying prescription volume from the CATALYST study is translating to cash.
🐻 Bear Case
Total operating expenses jumped 28% YoY to $214.8 million. While justified by the Lifyorli launch, this structurally higher cost base requires sustained, high-level revenue growth to prevent margin compression.
Despite the current euphoria, the authorized generic accounts for over 70% of Korlym volume at a ~30% discount, and Teva's patent litigation appeal remains an existential risk to the legacy endocrinology revenue.
⚖️ Verdict: 🟢🟢
Very Bullish. The commercial launch of Lifyorli is a game-changer that completely shifts the company's growth trajectory. Coupled with the resolution of Q1's operational hiccups, Corcept is executing perfectly on its dual-franchise strategy.
Key Themes
Lifyorli Delivers Blockbuster Launch
Lifyorli (relacorilant) generated $47.6 million in its first quarter on the market, an exceptional result for an oncology launch. Management noted that over 1,300 patients have initiated treatment since its March 2026 approval for platinum-resistant ovarian cancer. Inclusion in the NCCN Guidelines as a preferred regimen clearly accelerated early prescriber adoption, validating management's claim that this drug will become a new standard of care.
Endocrinology Demand Finally Realized
In Q1, management claimed record prescription volume was being masked by insurance authorization delays and a specialty pharmacy transition. Q2 data confirms this narrative: Korlym revenue jumped to $208.6 million. The expanded screening driven by the CATALYST and MOMENTUM trials is successfully flowing through the commercial funnel.
Rapidly Expanding Cost Base
A negative data point contradicting the pure growth narrative is the structural step-up in costs. Operating expenses reached $214.8M (up 28% YoY), driven by a massive increase in SG&A ($156.9M vs $103.8M YoY) to fund the Lifyorli launch. While operating margin recovered sequentially from Q1's disastrous -30%, the absolute level of spending means any stumble in Lifyorli's ongoing uptake will violently compress profitability.
Relacorilant Cushing's NDA Resubmitted
After a surprise Complete Response Letter (CRL) from the FDA in late 2025/early 2026, Corcept successfully resubmitted the New Drug Application for relacorilant in Cushing's syndrome in June 2026. The FDA assigned a PDUFA date of December 17, 2026. Securing this approval is critical to defending the endocrinology franchise against generic Korlym erosion.
Pipeline Readouts Approaching
Beyond the commercial products, Corcept is approaching a catalyst-rich year-end. Management expects results from the BELLA trial (relacorilant + nab-paclitaxel + bevacizumab in ovarian cancer) and the MONARCH Phase 2b trial (miricorilant in MASH) by the end of 2026. Furthermore, a Phase 3 trial for dazucorilant in ALS is set to begin early next year, seeking to replicate an 84% reduction in risk of death seen in Phase 2.
Other KPIs
Balance sheet remains exceptionally clean. Cash increased from $515.4M at the end of Q1, indicating strong free cash flow conversion despite the heavy SG&A ramp. This provides ample flexibility to continue pipeline investments or return capital to shareholders (management previously executed $245M in buybacks in 2025).
Reversing. A massive swing from the $31.2 million net loss reported in Q1. EPS came in at $0.36 (diluted), up from $0.29 a year ago. The sheer volume of high-margin Lifyorli sales outpaced the aggressive SG&A spending.
Guidance
Accelerating dramatically. Management raised the full-year guidance from the previous $950M-$1.05B range. The new midpoint of $1.15B implies a massive 51% YoY growth rate compared to FY25's $761.4M. This upgrade is entirely driven by the staggering early success of Lifyorli and the stabilization of the Cushing's pharmacy network.
Key Questions
Lifyorli Initial Stocking vs Organic Demand
Of the $47.6 million in Lifyorli revenue, how much represents initial inventory stocking at specialty pharmacies versus true underlying patient consumption?
Steady-State Margins
With SG&A surging to nearly $157M this quarter, at what revenue run-rate for Lifyorli do you expect marketing and launch costs to normalize, allowing operating margins to return to historical >20% levels?
Teva Litigation Update
Is there any update on the timeline for the appellate court ruling regarding Teva's generic Korlym? How is the authorized generic pricing dynamic evolving in the back half of the year?